Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

An Investigational Scan ([18F]F-AraG PET/CT) for the Detection of T-Cell Activation in Patients with Non-small Cell Lung Cancer Receiving Immunotherapy

Trial Status: administratively complete

This phase II trial studies if the radioactive compound called [18F]F-AraG is a helpful imaging agent during a PET/CT scan in detecting changes in anti-tumor immune response (or activation of T-cell) levels for non-small cell lung cancer (NSCLC) patients who will receive a cancer immunotherapy regimen. A PET scan uses radioactive material injected into the blood to show the internal workings of the body. A CT scan uses x-rays and a computer to produce a 3-dimensional image of the body. Combining the two scans may help doctors better understand the extent and the exact location of disease. The purpose of this trial is to find out how the radiotracer called [18F]F-AraG can help investigate changes in cancer’s anti-tumor immune response (or activation of T-cell) levels during PET/CT.